Sunshine Biopharma (SBFM) Cash from Operations (2010 - 2026)

Sunshine Biopharma has reported Cash from Operations for 17 years, with the latest figure at 2072100.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations fell 22.25% year-over-year to 2072100.0; the trailing twelve-month figure through Mar 2026 stood at 5708171.0 (up 48.27% YoY), and the FY2025 full-year result was 5331073.0, up 57.44% from the prior year.
• Cash from Operations for Q1 2026 stood at 2072100.0, down from 1616006.0 in the prior quarter.
• The five-year high for Cash from Operations was 457289.0 in Q3 2023, with the low at 4577784.0 in Q2 2024.
• Historically, Cash from Operations has averaged 1997142.41 across 5 years, with a median of 1695002.0 in 2025.
• Annual changes were most pronounced in 2022 — Cash from Operations slumped 619.81% — and 2025, when it jumped 71.77%.
• Sunshine Biopharma's Cash from Operations stood at 2246612.0 in 2022, then slipped by 19.72% to 2689676.0 in 2023, then dropped by 26.6% to 3405260.0 in 2024, then jumped by 52.54% to 1616006.0 in 2025, then fell by 28.22% to 2072100.0 in 2026.
• The last three Cash from Operations figures came in at 2072100.0 (Q1 2026), 1616006.0 (Q4 2025), and 727800.0 (Q3 2025), per Business Quant data.